168 related articles for article (PubMed ID: 32506594)
1. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
2. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
3. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
Li H; Xu Q; Wang Y; Chen K; Li J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
6. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
8. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
[TBL] [Abstract][Full Text] [Related]
9. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
10. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract][Full Text] [Related]
12. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
13. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
14. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
15. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
17. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
[TBL] [Abstract][Full Text] [Related]
18. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
[TBL] [Abstract][Full Text] [Related]
19. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
20. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
